These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

616 related items for PubMed ID: 25586297

  • 1. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer.
    Şendur MA, Aksoy S, Yorgun H, Ozdemir N, Yilmaz FM, Yazıcı O, Zungun C, Aytemir K, Zengin N, Altundag K.
    Curr Med Res Opin; 2015 Mar; 31(3):547-56. PubMed ID: 25586297
    [Abstract] [Full Text] [Related]

  • 2. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study.
    Onitilo AA, Engel JM, Stankowski RV, Liang H, Berg RL, Doi SA.
    Breast Cancer Res Treat; 2012 Jul; 134(1):291-8. PubMed ID: 22476854
    [Abstract] [Full Text] [Related]

  • 3. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
    Yu AF, Manrique C, Pun S, Liu JE, Mara E, Fleisher M, Patil S, Jones LW, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.
    Fallah-Rad N, Walker JR, Wassef A, Lytwyn M, Bohonis S, Fang T, Tian G, Kirkpatrick ID, Singal PK, Krahn M, Grenier D, Jassal DS.
    J Am Coll Cardiol; 2011 May 31; 57(22):2263-70. PubMed ID: 21616287
    [Abstract] [Full Text] [Related]

  • 8. Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.
    Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A.
    Heart; 2013 May 31; 99(9):634-9. PubMed ID: 23349345
    [Abstract] [Full Text] [Related]

  • 9. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH, Acuna SA, Sevick L, Yan AT, Brezden-Masley C.
    Med Oncol; 2017 Sep 31; 34(9):154. PubMed ID: 28779423
    [Abstract] [Full Text] [Related]

  • 10. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, Steingart RM, Hudis CA, Dang CT.
    Oncologist; 2017 Jun 31; 22(6):642-647. PubMed ID: 28341761
    [Abstract] [Full Text] [Related]

  • 11. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.
    Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A, PHARE trial investigators.
    Lancet Oncol; 2013 Jul 31; 14(8):741-8. PubMed ID: 23764181
    [Abstract] [Full Text] [Related]

  • 12. A Prospective Cohort Study on Cardiotoxicity of Adjuvant Trastuzumab Therapy in Breast Cancer Patients.
    Matos E, Jug B, Blagus R, Zakotnik B.
    Arq Bras Cardiol; 2016 Jul 31; 107(1):40-7. PubMed ID: 27305108
    [Abstract] [Full Text] [Related]

  • 13. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W, Sghaier S, Charfeddine S, Toumi N, Daoud J, Kammoun S, Khanfir A.
    Am J Clin Oncol; 2020 Jul 31; 43(7):510-516. PubMed ID: 32304433
    [Abstract] [Full Text] [Related]

  • 14. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
    Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, Cohen V, Banchs J, Carver JR, Wiegers SE, Martin RP, Picard MH, Gerszten RE, Halpern EF, Passeri J, Kuter I, Scherrer-Crosbie M.
    Circ Cardiovasc Imaging; 2012 Sep 01; 5(5):596-603. PubMed ID: 22744937
    [Abstract] [Full Text] [Related]

  • 15. Exploratory analysis of cardiac biomarkers in women with normal cardiac function receiving trastuzumab for breast cancer.
    Goel S, Simes RJ, Beith JM.
    Asia Pac J Clin Oncol; 2011 Sep 01; 7(3):276-80. PubMed ID: 21884439
    [Abstract] [Full Text] [Related]

  • 16. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real-world women with breast cancer.
    Tarantini L, Cioffi G, Gori S, Tuccia F, Boccardi L, Bovelli D, Lestuzzi C, Maurea N, Oliva S, Russo G, Faggiano P, Italian Cardio-Oncologic Network.
    J Card Fail; 2012 Feb 01; 18(2):113-9. PubMed ID: 22300778
    [Abstract] [Full Text] [Related]

  • 17. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity.
    Goel S, Liu J, Guo H, Barry W, Bell R, Murray B, Lynch J, Bastick P, Chantrill L, Kiely BE, Abdi E, Rutovitz J, Asghari R, Sullivan A, Harrison M, Kohonen-Corish M, Beith J.
    JACC Heart Fail; 2019 Sep 01; 7(9):795-804. PubMed ID: 31401102
    [Abstract] [Full Text] [Related]

  • 18. SAFE-HEaRt: Rationale and Design of a Pilot Study Investigating Cardiac Safety of HER2 Targeted Therapy in Patients with HER2-Positive Breast Cancer and Reduced Left Ventricular Function.
    Lynce F, Barac A, Tan MT, Asch FM, Smith KL, Dang C, Isaacs C, Swain SM.
    Oncologist; 2017 May 01; 22(5):518-525. PubMed ID: 28314836
    [Abstract] [Full Text] [Related]

  • 19. Trastuzumab induced cardiotoxicity in HER2 positive breast cancer patients attended in a tertiary hospital.
    Ayres LR, de Almeida Campos MS, de Oliveira Gozzo T, Martinez EZ, Ungari AQ, de Andrade JM, Pereira LR.
    Int J Clin Pharm; 2015 Apr 01; 37(2):365-72. PubMed ID: 25637407
    [Abstract] [Full Text] [Related]

  • 20. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC, de Boer M, Derksen MW, van den Berkmortel F, van Kampen RJ, van de Wouw AJ, Joore M, Peer PG, Voogd AC, Tjan-Heijnen VC.
    Oncologist; 2016 May 01; 21(5):555-62. PubMed ID: 27009939
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.